About Amicus Therapeutics (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:FOLD
- CUSIP: 03152W10
- Web: www.amicusrx.com
- Market Cap: $2.35494 billion
- Outstanding Shares: 164,566,000
- 50 Day Moving Avg: $14.44
- 200 Day Moving Avg: $11.10
- 52 Week Range: $4.41 - $16.60
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.73
- P/E Growth: -0.18
- Annual Revenue: $16.28 million
- Price / Sales: 137.37
- Book Value: $1.86 per share
- Price / Book: 7.31
- EBITDA: ($186,930,000.00)
- Net Margins: -1,279.88%
- Return on Equity: -61.25%
- Return on Assets: -20.08%
- Debt-to-Equity Ratio: 0.60%
- Current Ratio: 2.39%
- Quick Ratio: 2.35%
- Average Volume: 3.38 million shs.
- Beta: 1.83
- Short Ratio: 6.74
Frequently Asked Questions for Amicus Therapeutics (NASDAQ:FOLD)
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its earnings results on Monday, August, 7th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period last year, the business earned ($0.40) earnings per share. View Amicus Therapeutics' Earnings History.
When will Amicus Therapeutics make its next earnings announcement?
Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?
7 brokers have issued 12 month price objectives for Amicus Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they anticipate Amicus Therapeutics' share price to reach $18.07 in the next year. View Analyst Ratings for Amicus Therapeutics.
What are analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
- 1. According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (10/12/2017)
- 2. Cowen and Company analysts commented, "This morning, FOLD announced that after more recent FDA talks and written." (7/11/2017)
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 31,216,474 shares, a decrease of 10.0% from the September 15th total of 34,667,755 shares. Based on an average trading volume of 4,218,265 shares, the short-interest ratio is presently 7.4 days. Currently, 19.6% of the company's shares are short sold.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Taro Pharmaceutical Industries (TARO), Valeant Pharmaceuticals International (VRX), Akorn (AKRX), Opko Health (OPK), BTG plc (BTG), Hikma Pharmaceuticals Plc (HIK), Horizon Pharma PLC (HZNP), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Akcea Therapeutics (AKCA), Lannett Co (LCI), Amphastar Pharmaceuticals (AMPH) and SciClone Pharmaceuticals (SCLN).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- John F. Crowley J.D., Chairman of the Board, Chief Executive Officer
- Bradley L. Campbell, President, Chief Operating Officer
- William D. Baird III, Chief Financial Officer
- Daphne E. Quimi, Senior Vice President - Finance and Administration, Corporate Controller
- Kurt J. W. Andrews, Senior Vice President - Human Resources
- Hung Viet Do, Chief Scientific Officer
- Ellen S. Rosenberg, General Counsel and Corporate Secretary
- Jay A. Barth M.D., Chief Medical Officer
- Donald J. Hayden Jr., Lead Independent Director
- Robert A. Essner, Independent Director
Who owns Amicus Therapeutics stock?
Amicus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Mutual of America Capital Management LLC (0.05%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?
Amicus Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, John F Crowley, Life Sciences Maste Perceptive, Margaret G Mcglynn and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy Amicus Therapeutics stock?
Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amicus Therapeutics stock can currently be purchased for approximately $13.59.
Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.86)|
|Consensus Price Target: ||$18.07 (32.98% upside)|Consensus Price Target History for Amicus Therapeutics (NASDAQ:FOLD)
Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/6/2017||Goldman Sachs Group Inc||Reiterated Rating||Neutral -> Neutral||$17.00||N/A|
|10/5/2017||Chardan Capital||Reiterated Rating||Buy||$16.50 -> $18.50||N/A|
|10/4/2017||Robert W. Baird||Reiterated Rating||Outperform||$16.00 -> $18.00||N/A|
|10/4/2017||J P Morgan Chase & Co||Reiterated Rating||Overweight||N/A|
|10/4/2017||Leerink Swann||Reiterated Rating||Buy||$17.00 -> $20.00||Medium|
|10/4/2017||Bank of America Corporation||Boost Price Target||Buy||$15.00 -> $20.00||High|
|9/14/2017||Cowen and Company||Reiterated Rating||Outperform||$16.00 -> $18.00||Low|
|3/8/2016||Janney Montgomery Scott||Upgrade||Neutral -> Buy||$10.00 -> $12.00||N/A|
Earnings History for Amicus Therapeutics (NASDAQ:FOLD)Earnings History by Quarter for Amicus Therapeutics (NASDAQ FOLD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||Q2 2017||($0.37)||($0.34)||$6.96 million||$7.16 million||View||Listen|
|5/9/2017||Q1 2017||($0.37)||($0.39)||$4.16 million||$4.20 million||View||Listen|
|3/1/2017||Q4 2016||($0.33)||($0.32)||$3.16 million||$2.83 million||View||Listen|
|11/7/2016||Q3||($0.31)||($0.33)||$1.71 million||$2.10 million||View||Listen|
|11/6/2014||Q3 2014||($0.21)||($0.22)||$1.00 million||$0.29 million||View||N/A|
|8/7/2014||Q2 2014||($0.24)||($0.23)||$0.48 million||View||N/A|
|5/5/2014||Q1 2014||($0.23)||($0.25)||$0.20 million||$0.46 million||View||N/A|
|3/3/2014||Q4 13||($0.32)||($0.22)||$0.32 million||View||N/A|
|11/5/2012||Q312||($0.24)||($0.31)||$8.82 million||$5.80 million||View||N/A|
Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
2017 EPS Consensus Estimate: ($1.34)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amicus Therapeutics (NASDAQ:FOLD)
Insider Ownership Percentage: 3.40%Insider Trades by Quarter for Amicus Therapeutics (NASDAQ:FOLD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/18/2017||John F Crowley||CEO||Sell||71,735||$14.75||$1,058,091.25|| |
|10/16/2017||John F Crowley||CEO||Sell||449,295||$14.33||$6,438,397.35|| |
|10/12/2017||Daphne Quimi||SVP||Sell||7,000||$14.25||$99,750.00|| |
|10/12/2017||Hung Do||Insider||Sell||50,194||$14.25||$715,264.50|| |
|10/12/2017||Michael Raab||Director||Sell||10,000||$14.25||$142,500.00|| |
|10/12/2017||William D Baird III||CFO||Sell||40,000||$14.25||$570,000.00|| |
|9/26/2017||John F Crowley||CEO||Buy||1,395||$14.36||$20,032.20|| |
|7/13/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||1,500,000||$12.25||$18,375,000.00|| |
|6/19/2017||Jay Barth||Insider||Sell||30,000||$10.00||$300,000.00|| |
|5/19/2017||Hung Do||Insider||Sell||29,914||$8.00||$239,312.00|| |
|3/2/2017||Bradley L Campbell||COO||Sell||49,050||$8.00||$392,400.00|| |
|1/13/2017||Hung Do||Insider||Sell||25,000||$6.00||$150,000.00|| |
|12/30/2016||Perceptive Advisors Llc||Major Shareholder||Buy||94,750||$4.96||$469,960.00|| |
|12/29/2016||Perceptive Advisors Llc||Major Shareholder||Buy||142,125||$4.87||$692,148.75|| |
|12/23/2016||Perceptive Advisors Llc||Major Shareholder||Buy||85,275||$4.81||$410,172.75|| |
|12/22/2016||Perceptive Advisors Llc||Major Shareholder||Buy||189,500||$4.51||$854,645.00|| |
|11/9/2016||Daphne Quimi||SVP||Sell||8,546||$8.00||$68,368.00|| |
|11/1/2016||Hung Do||Insider||Sell||25,000||$7.00||$175,000.00|| |
|10/3/2016||Hung Do||Insider||Sell||25,000||$7.25||$181,250.00|| |
|9/20/2016||William D Baird III||CFO||Sell||20,500||$8.00||$164,000.00|| |
|9/6/2016||Hung Do||Insider||Sell||25,000||$7.00||$175,000.00|| |
|8/25/2016||Perceptive Advisors Llc||Insider||Sell||1,100,000||$6.81||$7,491,000.00|| |
|8/4/2016||Jay Barth||Insider||Sell||10,458||$7.00||$73,206.00|| |
|7/27/2016||Jay Barth||Insider||Sell||20,916||$7.00||$146,412.00|| |
|6/2/2016||Ellen Rosenberg||General Counsel||Buy||15,000||$7.67||$115,050.00|| |
|11/10/2015||Margaret G Mcglynn||Director||Buy||10,000||$10.27||$102,700.00|| |
|10/7/2015||Perceptive Advisors Llc||Major Shareholder||Buy||50,000||$6.27||$313,500.00|| |
|10/6/2015||Perceptive Advisors Llc||Major Shareholder||Buy||750,000||$6.71||$5,032,500.00|| |
|10/1/2015||Kenneth Peist||VP||Sell||10,000||$13.14||$131,400.00|| |
|9/21/2015||Bradley L. Campbell||COO||Sell||13,001||$16.78||$218,156.78|| |
|9/21/2015||William D. Baird III||CFO||Sell||15,236||$16.78||$255,660.08|| |
|9/15/2015||Hung Do||Insider||Sell||25,000||$17.75||$443,750.00|| |
|9/14/2015||Daphne Quimi||VP||Sell||2,500||$18.08||$45,200.00|| |
|7/16/2015||John F Crowley||CEO||Sell||16,025||$16.00||$256,400.00|| |
|7/14/2015||John F Crowley||CEO||Sell||142,250||$15.03||$2,138,017.50|| |
|7/13/2015||Glenn Sblendorio||Director||Sell||10,000||$15.00||$150,000.00|| |
|7/13/2015||John F Crowley||CEO||Sell||7,750||$15.01||$116,327.50|| |
|7/13/2015||Ken Valenzano||SVP||Sell||15,000||$15.00||$225,000.00|| |
|7/8/2015||Dipal Doshi||SVP||Sell||6,250||$13.87||$86,687.50|| |
|7/1/2015||Jayne Gershkowitz||SVP||Sell||10,649||$13.97||$148,766.53|| |
|7/1/2015||Kenneth Peist||VP||Sell||10,000||$13.98||$139,800.00|| |
|6/23/2015||Donald J Hayden Jr||Director||Sell||55,000||$14.01||$770,550.00|| |
|6/22/2015||Jeff Castelli||SVP||Sell||18,981||$13.94||$264,595.14|| |
|6/19/2015||Bradley L Campbell||COO||Sell||13,000||$13.26||$172,380.00|| |
|6/19/2015||Enrique Dilone||SVP||Sell||14,045||$13.26||$186,236.70|| |
|6/19/2015||William D Baird III||CFO||Sell||15,235||$13.26||$202,016.10|| |
|6/15/2015||Jeff Castelli||SVP||Sell||7,377||$14.17||$104,532.09|| |
|6/15/2015||Julie Yu||VP||Sell||8,195||$14.17||$116,123.15|| |
|6/8/2015||Jeff Castelli||SVP||Sell||17,312||$12.87||$222,805.44|| |
|6/8/2015||John F Crowley||CEO||Sell||55,000||$13.01||$715,550.00|| |
|5/11/2015||Jeff Castelli||SVP||Sell||10,000||$10.84||$108,400.00|| |
|5/11/2015||Kenneth Peist||VP||Sell||12,500||$10.84||$135,500.00|| |
|5/11/2015||William D Baird III||CFO||Sell||24,800||$10.84||$268,832.00|| |
|4/15/2015||Glenn Sblendorio||Director||Sell||20,000||$12.50||$250,000.00|| |
|4/15/2015||Ken Valenzano||VP||Sell||5,000||$12.50||$62,500.00|| |
|4/10/2015||John F Crowley||CEO||Sell||11,678||$12.00||$140,136.00|| |
|4/1/2015||Jeff Castelli||VP||Sell||9,489||$10.69||$101,437.41|| |
|1/5/2015||Jeff Castelli||VP||Sell||4,667||$9.00||$42,003.00|| |
|12/4/2014||John F Crowley||CEO||Sell||89,000||$8.36||$744,040.00|| |
|11/25/2014||Bradley L Campbell||COO||Sell||7,250||$8.00||$58,000.00|| |
|11/25/2014||Jeff Castelli||VP||Sell||8,103||$8.00||$64,824.00|| |
|11/25/2014||William D Baird III||CFO||Sell||10,000||$8.00||$80,000.00|| |
|11/19/2014||Perceptive Advisors Llc||Major Shareholder||Buy||2,100,000||$6.50||$13,650,000.00|| |
|10/27/2014||Plc Glaxosmithkline||Major Shareholder||Sell||11,315,825||$5.29||$59,860,714.25|| |
|10/3/2014||Jeff Castelli||VP||Sell||8,552||$7.00||$59,864.00|| |
|10/3/2014||William D Baird III||CFO||Sell||10,000||$7.00||$70,000.00|| |
|10/2/2014||Julie Yu||VP||Sell||4,759||$5.99||$28,506.41|| |
|9/29/2014||Daphne Quimi||VP||Sell||10,738||$6.10||$65,501.80|| |
|9/29/2014||William D Baird III||CFO||Sell||25,311||$6.09||$154,143.99|| |
|8/27/2014||Glenn Sblendorio||Director||Sell||10,000||$6.50||$65,000.00|| |
|8/27/2014||Jayne Gershkowitz||VP||Sell||5,000||$7.00||$35,000.00|| |
|8/25/2014||Bradley L Campbell||COO||Sell||7,000||$6.00||$42,000.00|| |
|8/25/2014||Jayne Gershkowitz||VP||Sell||5,000||$6.00||$30,000.00|| |
|8/20/2014||Bradley L Campbell||COO||Sell||18,750||$5.40||$101,250.00|| |
|8/20/2014||Enrique Dilone||VP||Sell||12,810||$5.40||$69,174.00|| |
|6/30/2014||Perceptive Advisors Llc||Major Shareholder||Buy||4,000,000||$3.50||$14,000,000.00|| |
|11/20/2013||Plc Glaxosmithkline||major shareholder||Buy||1,500,000||$2.00||$3,000,000.00|| |
|3/15/2013||Sol J Barer||Director||Buy||25,000||$3.40||$85,000.00|| |
|11/13/2012||Joan Winterbottom||SVP||Buy||1,665||$4.54||$7,559.10|| |
Headline Trends for Amicus Therapeutics (NASDAQ:FOLD)
Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
Loading headlines, please wait.
Amicus Therapeutics (FOLD) Chart for Saturday, October, 21, 2017